Accrol Group Holdings plc (LON:ACRL) has delivered a solid set of FY results, which were well flagged at the adjusted EBITDA level, but outperformed our adjusted EPS by 1.7%. We
Accrol Group Holdings plc (LON:ACRL), the UK’s leading independent tissue converter, has announced its audited Final Results for the year ended 30 April 2021, which show a transformed business, delivering
Accrol Group Holdings plc (LON:ACRL), one of the UK’s leading independent tissue converters, has announced that it will release its Final Results for the year ended 30 April 2021 on
Accrol Group Holdings plc (LON:ACRL), the UK’s leading independent tissue convertor, has announced the following trading update ahead of its Final Results for the year ended 30 April 2021, which
Zeus Capital’s Mike Allen discusses Accrol Group Holdings plc in this exclusive interview with DirectorsTalk.
Accrol Group Holdings plc (LON:ACRL), one of the UK’s leading independent tissue converters, has announced that the Group has completed the acquisition of John Dale Limited, a highly scalable flushable
Premier Miton Investors and Diverse Income Trust’s Gervais Williams discusses current events and the effects on small-caps in this exclusive interview with DirectorsTalk.
Accrol Group Holdings plc (LON:ACRL) is the topic of conversation when Mike Allen, Head of Research at Zeus Capital joins DirectorsTalk. With the company producing is half year trading update Mike talks us
Accrol Group Holdings plc (LON:ACRL), the UK’s leading independent tissue converter, has announced its results for the six months ended 31 October 2020. Summary of progress The Group’s progress continues
Accrol Group Holdings plc (LON:ACRL) has announced that, as part of the Group’s Half Yearly Results roadshow, the management will host an online investor presentation and Q&A session. This will
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
